Drugs / PD5K3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06527781 | Nov 2023 → May 2024 | acute lymphoblastic leukemia, lymphoblastic lymphoma | Chongqing Peg-Bio Biopharm Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD5K3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06527781 ↗ |